Ofev (nintedanib) — Medica

Initial criteria

• age ≥ 18 years
• forced vital capacity (FVC) ≥ 40% of the predicted value
• diagnosis confirmed by either high-resolution computed tomography findings indicating usual interstitial pneumonia OR a surgical lung biopsy demonstrating usual interstitial pneumonia
• prescribed by or in consultation with a pulmonologist

Reauthorization criteria

• age ≥ 18 years
• patient has experienced a beneficial response to therapy over the last year (or since baseline if < 1 year) such as reduction in anticipated decline in FVC, six-minute walk distance, and/or number or severity of idiopathic pulmonary fibrosis exacerbations
• prescribed by or in consultation with a pulmonologist

Approval duration

1 year